Clinical significance of serum M30 and M65 levels in patients with breast cancer

Biomedicine and Pharmacotherapy

Volumn 68, Issue 8, 2014, Pages 1135-1140

  Tas, Faruk ^a   Karabulut, Senem ^a   Yildiz, Ibrahim ^a   Duranyildiz, Derya ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Breast cancer; M30; M65; Serum

Indexed keywords

CYTOKERATIN 18; M65 ANTIGEN, HUMAN; PEPTIDE FRAGMENT; TUMOR MARKER;

ADULT; AGED; BLOOD; BREAST NEOPLASMS; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; SURVIVAL RATE; TRENDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; KERATIN-18; MIDDLE AGED; PEPTIDE FRAGMENTS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84916236987     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.10.021     Document Type: Article

References (23)

1. Chu P.G., Weiss L.M. Keratin expression in human tissues and neoplasms. Histopathol 2000, 40:403-439.
2. Cummings J., Hodgkinson C., Odedra R., Sini P., Heaton S.P., Mundt K.E., et al. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol Cancer Ther 2008, 7:455-463.
3. De Haas E.C., di Pietro A., Simpson K.L., Meijer C., Suurmeijer A.J.H., Lancashire L.J., et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 2008, 10:1041-1048.
4. Weber K., Osborn M., Moll R., Wiklund B., Luning B. Tissue polypeptide antigene (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker. EMBO J 1984, 3:2707-2714.
5. Silen A., Wiklund B., Andersson E.L., Nilsson S. A novel IRMA and ELISA for quantifying cytokeratin 8 and 18 fragments in the sera of healthy individuals and cancer patients. Scand J Clin Lab Invest 1995, 55:153-161.
6. Barak V., Goike H., Panaretakis K.W., Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004, 37:529-540.
7. Greystoke A., Cummings J., Ward T., Simpson K., Renehan A., Butt F., et al. Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol 2008, 19:990-995.
8. Bilici A., Ustaalioglu B.B., Ercan S., Seker M., Yilmaz B.E., Orcun A., et al. The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer. Tumour Biol 2012, 33:2201-2208.
9. Bilici A., Ustaalioglu B.B.O., Ercan S., Orcun A., Seker M., Salepci T., et al. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?. Cancer Chemother Pharmacol 2011, 68:309-316.
10. Yaman E., Coskun U., Sancak B., Buyukberber S., Ozturk B., Benekli M. Serum M30 levels are associated with survival in advanced gastric carcinoma patients. Int Immunopharmacol 2010, 10:719-722.
11. Dive C., Smith R.A., Garner E., Ward T., George-Smith S.S., Campbell F., et al. Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer 2010, 102:577-582.
12. Ausch C., Buxhofer-Ausch V., Olszewski U., Hinterberger W., Ogris E., Schiessel R., et al. Caspase-cleaved cytokeratin 18 fragment (m30) as marker of postoperative residual tumor load in colon cancer patients. Eur J Surg Oncol 2009, 35:1164-1168.
13. Ausch C., Buxhofer-Ausch V., Olszewski U., Schiessel R., Ogris E., Hinterberger W., et al. Circulating cytokeratin 18 fragment M65- a potential marker of malignancy in colorectal cancer patients. J Gastrointest Surg 2009, 13:2020-2026.
14. Koelink P.J., Lamers C.B., Hommes D.W., Verspaget H.W. Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer 2009, 9:88.
15. Ulukaya E., Yilmaztepe A., Akgoz S., Linder S., Karadag M. The levels of caspase-cleaved cytokine 18 are elevated in serum from patients with lung cancer, helpful to predict the survival. Lung Cancer 2007, 56:399-404.
16. Ustaalioglu B.O., Bilici A., Ercan S., Orcun A., Seker M., Ozkan A., et al. Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls. Clin Transl Oncol 2012, 14:356-361.
17. Ozturk B., Coskun U., Sancak B., Yaman E., Buyukberber S., Benekli M. Elevated serum levels of M30, M65 in patients with locally advanced head, neck tumors. Int Immunopharmacol 2009, 9:645-648.
18. Biven K., Erdal H., Hagg M., Ueno T., Zhou R., Lynch M., et al. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 2003, 8:263-268.
19. Ueno T., Toi M., Biven K., Bando H., Ogawa T., Linder S. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 2003, 39:769-774.
20. Demiray M., Ulukaya E.E., Arslan M., Gokgoz S., Saraydaroglu O., Ercan I., et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest 2006, 24:669-676.
21. Olofsson M.H., Ueno T., Pan Y., Xu R., Cai F., van der Kuip H., et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 2007, 13:3198-3206.
22. Ulukaya E., Karaagac E., Ari F., Oral A.Y., Adim S.B., Tokullugil A.H., et al. Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients. Radiol Oncol 2011, 45:116-122.
23. Stoetzer O.J., Fersching D.M.I., Salat C., Steinkohl O., Gabka C.J., Hamann U., et al. Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and surviving. Cancer Lett 2013, 336:140-148.